Relmada Therapeutics (RLMD) AI Stock Analysis

• Market Cap: $9.08M
• Dividend Yield: N/A
• Average Volume (3M): 403.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: N/A
• EPS Growth: 19.21%
• Country: US
• Employees: 20
• Sector: Healthcare
• Sector Strength: 62
• Industry: Biotechnology
• EPS (TTM): -2.65
• Shares Outstanding: 33,191,624
• 10 Day Avg. Volume: 382,314
• 30 Day Avg. Volume: 403,855
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1.00
• Price Target Upside: 233.33% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

Relmada Therapeutics faces significant challenges with its current financial performance, characterized by zero revenue and high operational costs. The company's recent strategic acquisitions and pipeline developments offer potential for future growth, but concerns remain regarding cash burn and the lack of current revenue. The technical analysis indicates a lack of strong momentum, and the valuation remains difficult due to the negative P/E ratio.

Positive Factors

Drug Efficacy

Sepranolone has shown promising efficacy and safety in Phase 2a studies, providing a 69% improvement in quality of life for Tourette syndrome patients.

Market Potential

The in-licensing of NDV-01 for treating NMIBC represents a multi-billion opportunity for Relmada Therapeutics Inc.

Product Development

Relmada's NDV-01 intravesical procedure is quick, requires no anesthesia, and doesn't need new equipment, offering significant advantages over current treatments.

Negative Factors

Financial Outlook

The firm's rating remains neutral, indicating cautious optimism and potential concerns not entirely alleviated by the current developments.

Product Pipeline

The interim analysis concluded futility of REL-1017 in RELIANCE II, which is disappointing given previous evidence and similar approved products.

Stock Rating

Based on current updates, a shift to the sidelines with a Market Perform rating and a new $1 price target is suggested.

Relmada Therapeutics Business Overview & Revenue Model

Company Description

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of central nervous system (CNS) diseases. The company is primarily engaged in the research and development of novel compounds and formulations aimed at addressing unmet medical needs within the CNS sector. Relmada's lead product candidate is REL-1017 (esmethadone), an NMDA receptor antagonist, which is being investigated for the treatment of major depressive disorder (MDD).

How the Company Makes Money

Relmada Therapeutics primarily generates revenue through strategic partnerships, collaborations, and funding related to the research and development of its pipeline therapies. As a clinical-stage company, Relmada does not yet have products on the market generating sales revenue. Instead, it relies on investments, grants, and milestone payments from partners who are interested in the potential of its drug candidates. These collaborations can involve licensing agreements or co-development arrangements, which provide financial support for the ongoing development of their therapies. The company's future revenue streams are expected to depend on the successful clinical trials and subsequent commercialization of its lead candidates, particularly if regulatory approvals are obtained.

Relmada Therapeutics Financial Statement Overview

Summary

Relmada Therapeutics is in a challenging financial position with zero revenue and high operational expenditures typical for early-stage biotech firms. Despite strong cash reserves, the lack of revenue and negative cash flows highlight the need for successful product development and market entry.

Income Statement

Relmada Therapeutics has consistently reported zero revenue over the years, indicating that the company is still in the development stage, typical for biotech firms. The net income has been negative, showing significant losses, primarily due to high research and development expenses. There is no revenue growth, gross profit, or positive EBIT margin, which are critical for long-term sustainability.

Balance Sheet

The company's balance sheet shows adequate liquidity, with significant cash reserves compared to its liabilities, resulting in a negative net debt. However, the lack of revenue generation could pose a long-term risk if cash reserves are depleted without incoming revenue. The equity ratio is strong, but the absence of debt may limit financial leverage for expansion once products reach commercialization.

Cash Flow

Relmada Therapeutics has experienced negative operating and free cash flows due to ongoing operational expenses without revenue offset. The persistent negative free cash flow indicates dependency on external financing, which could be a concern if capital markets become less favorable. The cash flow situation highlights a need for strategic planning towards revenue generation.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	-1.26K	-3.75K
	EBIT
-91.64M	0.00	-103.70M	-161.25M	-125.70M	-60.84M
	EBITDA
-41.83M	0.00	4.91M	-157.04M	-125.75M	-59.45M
	Net Income Common Stockholders
-86.49M	0.00	-98.79M	-157.04M	-125.75M	-59.46M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.50K	44.91M	96.32M	148.32M	211.91M	117.09M
	Total Assets
10.19K	45.82M	97.55M	152.91M	223.33M	118.19M
	Total Debt
0.00	0.00	0.00	0.00	0.00	0.00
	Net Debt
-7.50K	-3.86M	-4.09M	-5.40M	-44.44M	-2.50M
	Total Liabilities
12.00K	10.30M	12.19M	12.47M	15.06M	12.60M
	Stockholders Equity
-1.81K	35.52M	85.36M	140.44M	208.26M	105.58M
Cash Flow		Free Cash Flow
-53.21M	0.00	-51.66M	-103.80M	-91.87M	-27.81M
	Operating Cash Flow
-53.21M	0.00	-51.66M	-103.80M	-91.87M	-27.81M
	Investing Cash Flow
47.96M	51.56M	50.45M	19.73M	-54.12M	-34.45M
	Financing Cash Flow
33.68K	-40.34K	-98.46K	45.02M	187.94M	28.47M

Relmada Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RLMD, the sentiment is Neutral. The current price of 0.3 is above the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.31, and below the 200-day MA of 2.07, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 36.82 is Neutral, neither overbought nor oversold. The STOCH value of 31.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RLMD.

Relmada Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACAD	76 Outperform	$2.77B	12.00	38.89%	―	31.85%	―
NBIX	68 Neutral	$11.03B	32.51	14.16%	―	24.81%	33.67%
AXSM	51 Neutral	$5.69B	―	-231.63%	―	42.53%	-15.29%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
SAGE	48 Neutral	$483.24M	―	-63.37%	―	-52.30%	27.13%
RLMD	42 Neutral	$9.08M	―	-132.33%	―	―	19.21%
XENE	39 Underperform	$2.57B	―	-27.85%	―	―	-10.19%

Relmada Therapeutics Corporate Events

Relmada Therapeutics Secures Exclusive License for NDV-01

On March 24, 2025, Relmada Therapeutics entered into an exclusive license agreement with Trigone Pharma for NDV-01, a novel sustained-release formulation of gemcitabine and docetaxel for treating Non-Muscle Invasive Bladder Cancer. This agreement grants Relmada worldwide rights, excluding India, Israel, and South Africa, and involves a $3.5 million upfront payment, potential milestone payments up to $200 million, and a 3% royalty on net sales. NDV-01 is expected to be a first-line therapy for NMIBC, offering significant clinical benefits, and its Phase 2 data will be presented at the American Urological Association meeting in April 2025.

Relmada Therapeutics Acquires Sepranolone for CNS Portfolio

Relmada Therapeutics has entered into an Asset Purchase Agreement with Asarina Pharma AB to acquire Sepranolone, a Phase 2b ready neurosteroid being developed for Tourette Syndrome and other compulsive disorders, for €3 million. This acquisition aligns with Relmada’s strategy to enhance its CNS disorder treatment portfolio, as Sepranolone has shown promising Phase 2a results, offering significant tic reduction and quality of life improvements without serious side effects, potentially positioning it as a first-line treatment for Tourette Syndrome.

Relmada Therapeutics Strengthens Leadership with New COO

Relmada Therapeutics has announced the appointment of Paul Kelly as Chief Operating Officer effective January 1, 2025, which is expected to strengthen its leadership team. The company has made strategic adjustments to executive compensation to manage expenses, including suspending retention payments and withholding salary increases and bonuses for fiscal 2025.